Axovant Gene Therapies (NASDAQ:AXGT) Sees Large Volume Increase

Shares of Axovant Gene Therapies Ltd (NASDAQ:AXGT) saw unusually-high trading volume on Thursday . Approximately 1,226,780 shares traded hands during trading, an increase of 164% from the previous session’s volume of 464,904 shares.The stock last traded at $7.33 and had previously closed at $6.63.

AXGT has been the subject of a number of research reports. Cowen reiterated a “hold” rating on shares of Axovant Gene Therapies in a research report on Tuesday. Svb Leerink began coverage on shares of Axovant Gene Therapies in a research report on Friday, June 21st. They set an “outperform” rating and a $18.00 target price for the company. JMP Securities increased their price target on shares of Axovant Gene Therapies from $8.00 to $28.00 and gave the stock an “outperform” rating in a report on Thursday, June 6th. Evercore ISI began coverage on shares of Homology Medicines in a report on Thursday, April 11th. They issued an “outperform” rating and a $29.00 price target on the stock. Finally, ValuEngine downgraded shares of Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $28.76.

The stock has a market capitalization of $152.97 million, a PE ratio of -0.91 and a beta of 1.28. The company has a quick ratio of 2.63, a current ratio of 2.63 and a debt-to-equity ratio of 0.41. The firm has a fifty day moving average price of $6.16.



Axovant Gene Therapies (NASDAQ:AXGT) last announced its quarterly earnings results on Tuesday, June 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.70) by $1.25. As a group, research analysts expect that Axovant Gene Therapies Ltd will post -5.71 earnings per share for the current year.

In other news, CEO Pavan Cheruvu purchased 7,500 shares of the stock in a transaction dated Friday, June 14th. The shares were purchased at an average cost of $5.21 per share, with a total value of $39,075.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 3.20% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in AXGT. Primecap Management Co. CA acquired a new position in Axovant Gene Therapies during the 1st quarter worth $1,400,000. Marshall Wace LLP acquired a new position in shares of Axovant Gene Therapies during the first quarter valued at about $272,000. Finally, Sphera Funds Management LTD. acquired a new position in shares of Axovant Gene Therapies during the first quarter valued at about $6,794,000.

Axovant Gene Therapies Company Profile (NASDAQ:AXGT)

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.

Featured Article: Should You Consider an Index Fund?

Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.